BofA analyst Tazeen Ahmad raised the firm’s price target on Denali Therapeutics to $29 from $25 and keeps a Buy rating on the shares after Denali reached alignment with the FDA on a path to accelerated approval for tividenofusp alfa, or tivi, for Hunter syndrome using cerebrospinal heparan sulfate as a surrogate biomarker. The firm is encouraged by tivi’s differentiated profile with potential to address both systemic and CNS symptoms in Hunter syndrome, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
- Denali Therapeutics plans to file for accelerated approval of tividenofusp alfa
- Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
- Denali Therapeutics price target raised to $32 from $26 at Citi
- Denali Therapeutics price target lowered to $90 from $95 at H.C. Wainwright
Questions or Comments about the article? Write to editor@tipranks.com